

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

  
\_\_\_\_\_  
Signature of Authorized Individual\*

10/21/2020  
\_\_\_\_\_  
Date

JON LOWME  
\_\_\_\_\_  
Printed Name of Authorized Individual

10/21/2020  
\_\_\_\_\_  
Date

\*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

**SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)**

Case No.	Debtor Entity Name:	Net Receipts <sup>2</sup>	Net Disbursements <sup>1</sup>
087-19-23648	PURDUE PHARMA INC.	\$ -	\$ 998,442
087-19-23649	PURDUE PHARMA L.P.	152,726,218	130,726,105
087-19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	-
087-19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	15,947
087-19-23652	PURDUE PHARMACEUTICALS L.P.	-	4,068,270
087-19-23653	IMBRIUM THERAPEUTICS L.P.	4,442	2,686,611
087-19-23654	ADLON THERAPEUTICS L.P.	-	3,295,120
087-19-23655	GREENFIELD BIO VENTURES L.P.	-	141,741
087-19-23656	SEVEN SEAS HILL CORP.	-	-
087-19-23657	OPHIR GREEN CORP.	-	-
087-19-23658	PURDUE PHARMA OF PUERTO RICO	-	2,586
087-19-23659	AVRIO HEALTH L.P.	-	5,082,851
087-19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	1,405
087-19-23661	PURDUE NEUROSCIENCE COMPANY	-	-
087-19-23662	NAYATT COVE LIFESCIENCE INC.	-	1,540,424
087-19-23663	BUTTON LAND L.P.	-	1,485
087-19-23664	PAUL LAND INC.	-	400
087-19-23665	QUIDNICK LAND L.P.	-	1,242
087-19-23666	RHODES ASSOCIATES L.P.	-	-
087-19-23667	RHODES PHARMACEUTICALS L.P.	8,086,474	23,668,773
087-19-23668	RHODES TECHNOLOGIES	1,753,696	3,083,995
087-19-23669	UDF LP	-	-
087-19-23670	SVC PHARMA LP	-	508,146
087-19-23671	SVC PHARMA INC.	-	-
<b>Totals:</b>		<b>\$ 162,570,829</b>	<b>\$ 175,823,541</b>

**Footnotes**

- 1) The Net Disbursements exclude intercompany transactions among Debtors
- 2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
September 30, 2020

**BANK ACCOUNT BALANCES (\$)**

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	\$ 750,229
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,865,249
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,002,156
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	5,250,082
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,660,367
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Money Market Account	200,006,701
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Money Market Account	100,296,603
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx8720	Money Market Account	100,183,411
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	53,825,256
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	574,581,737
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	18,782,034
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	244,041
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx6017	Trust	15,149,112
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,273,449
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	59,181,068
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,017,014
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	93,025,008
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,391,765
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx4018	Trust	25,105,767
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	1,331,181
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	125,966
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
September 30, 2020

**BANK ACCOUNT BALANCES (\$)**

<b>Debtor</b>	<b>Bank</b>	<b>Account Number</b>	<b>Description</b>	<b>Balance as of Month End</b>
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-
Rhodes Technologies	JP Morgan Chase	xxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
<b>Total</b>				<b>\$ 1,303,398,858</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

CONSOLIDATED STATEMENT OF OPERATIONS (\$M) <sup>1,2</sup>  
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Net Sales	\$ 61	\$ 686	\$ 997
Cost of Goods Sold	(23)	(154)	(254)
Gross Profit	38	532	742
Sales and Promotion	(8)	(79)	(117)
Research and Development	(11)	(59)	(93)
General and Administrative	(7)	(69)	(109)
Legal Fees - Ordinary Course	-	(9)	(12)
Medical Affairs	(3)	(25)	(36)
Milestones & Alliances	1	(5)	(6)
Health Care Reform Fee	(1)	(8)	(12)
Other US	-	(2)	(3)
Incentive Bonus	3	(25)	(41)
Total Operating Expenses	(26)	(281)	(429)
Operating Profit	12	251	314
Legal Fees - Non-Recurring	(35)	(275)	(372)
Other <sup>4</sup>	(58)	(72)	(79)
Total Non-Operating Expenses	(93)	(347)	(451)
Profit <sup>5</sup>	\$ (81)	\$ (96)	\$ (137)

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

4) Includes non-cash write downs of \$58M related to Rhodes Technologies assets.

5) The debtors historically updated contingencies as part of their year-end review with their auditors, Ernst and Young. Consistent with that practice, the Debtors have not assessed the need to adjust accruals for settlements as of September 30, 2020. The Debtors note, however, that they are in active settlement discussions with various creditors to settle outstanding claims and will incorporate any settlements as appropriate when the accruals are updated.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000) <sup>1,2</sup>

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Management Fee Income	\$ 29	\$ 262	\$ 377
General and Administrative Expenses	(4)	(29)	(58)
Operating Income	25	233	319
		-	
Income from Unconsolidated Associated Companies	(124)	(160)	(1,086)
Total Other Income	(124)	(160)	(1,086)
		-	
Pre-Tax Income	(99)	73	(767)
		-	
Income Tax Provision	27	(19)	193
		-	
Net Income	\$ (72)	\$ 54	\$ (574)

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
September 30, 2020

CONSOLIDATED BALANCE SHEET (\$M) <sup>1,2</sup>	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
<b>ASSETS</b>	
<b>CURRENT ASSETS</b>	
Cash & Cash Equivalents	\$ 1,048
Assets Held for Sale	1
Available For Sale Investments	1
Accounts Receivable, Net	129
Due From Associated Companies	5
Other Receivables	3
Inventories, Net	105
Prepaid Expenses & Other Current Assets	60
Restricted Cash	106
<b>TOTAL CURRENT ASSETS</b>	<b>1,458</b>
Property and Equipment, net	78
Investments at Cost	43
Investments in Associated Companies	-
Restricted Cash - Long-Term	148
Intangible Assets, Net	97
Other Assets	3
<b>TOTAL ASSETS</b>	<b>\$ 1,827</b>
<b>LIABILITIES AND EQUITY</b>	
<b>CURRENT LIABILITIES</b>	
Accounts Payable	\$ 42
Accrued Expenses	373
Due to Associated Companies	1
<b>TOTAL CURRENT LIABILITIES</b>	<b>416</b>
Other Liabilities	93
Due to Associated Companies	11
Liabilities Subject to Compromise <sup>3,4</sup>	3,017
<b>TOTAL LIABILITIES</b>	<b>3,537</b>
<b>EQUITY</b>	
Retained Earnings & Partners' Capital	(1,665)
Accumulated Other Comprehensive Loss	(45)
<b>TOTAL EQUITY</b>	<b>(1,710)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$ 1,827</b>

**Footnotes**

1) The numbers reflected in the Consolidated Balance Sheet are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

4) The debtors historically updated contingencies as part of their year-end review with their auditors, Ernst and Young. Consistent with that practice, the Debtors have not assessed the need to adjust accruals for settlements as of September 30, 2020. The Debtors note, however, that they are in active settlement discussions with various creditors to settle outstanding claims and will incorporate any settlements as appropriate when the accruals are updated.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
September 30, 2020

**PURDUE PHARMA, INC. BALANCE SHEET (\$000) <sup>1,2</sup>**

		<b>Book Value</b>
<b>Assets</b>		
Currents assets:		
Cash and cash equivalents	\$	1,156
Prepaid expenses		374
Due from Associated Companies		90
Other receivables		-
<b>Total current assets</b>		<b>1,620</b>
Investments		10,161
Deferred income taxes		147
<b>Total assets</b>	<b>\$</b>	<b>11,928</b>
<b>Liabilities and equity</b>		
Current liabilities:		
Accounts payable	\$	463
Due to Associated Companies		181
Accrued Expenses		178
<b>Total liabilities</b>		<b>822</b>
Common stock		1
Additional paid-in capital		499
Retained earnings		10,671
Accumulated other comprehensive loss		(65)
<b>Total equity</b>		<b>11,106</b>
<b>Total liabilities and equity</b>	<b>\$</b>	<b>11,928</b>

**Footnotes**

1) The numbers reflected in the Consolidated Balance Sheet are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

**SCHEDULE OF POST PETITION TAXES**

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



---

Signature

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Compensation</b>		
Chomiak, Caroline	\$ -	\$ 261,662
Kesselman, Marc L <sup>2</sup>	163,554	4,018,900
Landau, Craig J	879,102	3,726,417
Lowne, Jonathan R	76,258	1,880,760
Lundie, David R	66,841	1,552,187
Mancinelli II, Vincent F	41,042	894,071
Mazzi, Christian	-	439,030
Medeiros, Paul	56,095	1,220,469
Shamblen, Randy	40,170	879,324
Strassburger, Philip C	104,220	1,614,331
<b>Total Compensation</b>	<b>1,427,281</b>	<b>16,487,152</b>
<b>Director Fees</b>		
Boer, F Peter	175,000	875,000
Buckfire, Kenneth A	175,000	875,000
Cola, Michael	175,000	875,000
Collins, Michael J	-	25,000
Dubel, John	175,000	875,000
Miller, Robert S	208,333	2,291,667
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	175,000	875,000
<b>Total Director Fees</b>	<b>1,083,333</b>	<b>6,716,667</b>
<b>T&amp;E Reimbursements</b>		
Boer, F Peter	-	10,907
Buckfire, Kenneth A	-	1,565
Chomiak, Caroline	-	30,408
Cola, Michael	-	1,388
Debone, Louis	-	1,245
Dubel, John	-	4,714
Kesselman, Marc L	79	49,544
Landau, Craig J	7,063	73,370
Lowne, Jonathan R	-	1,834
Lundie, David R	-	28,913
Mancinelli II, Vincent F	39	41,357
Mazzi, Christian	-	3,734
Medeiros, Paul	961	38,609
Miller, Robert S	-	9,765
Pickett, Cecil	-	1,298
Shamblen, Randy	39	11,587
Strassburger, Philip C	155	16,150
<b>Total T&amp;E Reimbursements</b>	<b>8,336</b>	<b>326,388</b>
<b>Housing Payments</b>		
Kesselman, Marc L	4,673	65,195
<b>Total Housing Payments</b>	<b>4,673</b>	<b>65,195</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b><i>Indemnification Payments</i></b>		
Baker, Stuart D <sup>3</sup>	170,167	1,034,911
Butcher, James A	-	527
Friedman, Michael	42,392	190,234
Landau, Craig J	326,910	1,743,436
Lundie, David R	21,878	21,878
Motahari, Saeed	-	24,680
Roncalli, Anthony	75,064	393,250
Stewart, John	31,815	177,041
Timney, Mark	24,249	1,080,701
Purdue Pharma Inc Independent Directors <sup>4</sup>	-	1,132,033
<b>Total Indemnification Payments</b>	<b>692,473</b>	<b>5,798,690</b>
<b><i>Payments to Independent Associated Companies</i></b>		
Mundibiopharma Ltd	-	55,332
Mundipharma DC BV	-	263,503
Mundipharma International Ltd	-	11,053
Mundipharma International Technical Operations Ltd	12,907	17,386
Mundipharma IT Services Ltd	-	278,603
Mundipharma Laboratories GmbH	-	916,775
Mundipharma Research Ltd	-	113,807
Mundipharma Singapore Holdings Pte Ltd	-	60,675
One Stamford Realty L.P.	896,497	12,665,601
Pharmaceutical Research Associates Inc.	-	957,382
Purdue Pharma Canada	278,271	4,677,119
TXP Services Inc. <sup>5</sup>	58,333	6,619,945
<b>Total Payments to Independent Associated Companies</b>	<b>1,246,009</b>	<b>26,637,181</b>
<b>Total Payments to Insiders</b>	<b>\$ 4,462,106</b>	<b>\$ 56,031,273</b>

**Footnotes**

- 1) Represents payments made since the Commencement Date.
- 2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.
- 3) Indemnification payments made in June 2020 on behalf of Stuart D. Baker were inadvertently in amounts exceeding the 50% reimbursement rate approved by the Special Committee of Purdue Pharma Inc.'s Board of Directors, totaling \$12,390. Overpayments are in the process of being reversed through future invoice credits, repayment from respective law firms, and/or reimbursement from Stuart D. Baker. Currently, \$8,845 of this total remains outstanding.
- 4) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snyderman, Ralph.
- 5) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1,2</sup>
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	\$ 3,809,542	\$ 48,204,619
AlixPartners, LLP	2,066,579	12,915,464
PJT Partners LP	178,920	2,079,940
Ernst & Young	331,000	851,000
Cornerstone Research	147,162	147,162
Prime Clerk LLC	2,655,280	47,540,611
<b>Total Estate Professionals</b>	<b>9,188,483</b>	<b>111,738,795</b>
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	3,357,745	31,250,884
Bayard, P.A.	-	949,214
Cole Schotz P.C.	503,831	4,112,748
Jefferies LLC	379,855	2,109,825
KPMG	1,024,553	2,887,883
Province, Inc.	884,888	10,388,601
Kurtzman Carson Consultants LLC	116,773	334,277
Bedell Cristin	10,970	35,201
<b>Total Creditor Committee Professionals</b>	<b>6,278,613</b>	<b>52,068,632</b>
<i>Ad Hoc Committee Professionals</i>		
Kramer Levin Naftalis & Frankel LLP	294,618	4,313,746
Brown Rudnick LLP	132,020	1,979,064
Gilbert LLP	481,508	2,317,727
Otterbourg PC	62,138	970,597
FTI Consulting, Inc	611,243	5,071,848
Houlihan Lokey	-	-
Compass Lexecon	-	-
Coulter & Justice	-	-
<b>Total Ad Hoc Committee Professionals</b>	<b>1,581,528</b>	<b>14,652,983</b>
<i>Special Counsel to the Debtors</i>		
Arnold Porter & Kaye Scholer	100,366	1,330,786
Dechert LLP	-	-
Jones Day	137,001	1,966,306
King & Spalding LLP	2,007,047	11,123,109
Skadden, Arps, Slate, Meagher & Flom LLP	2,268,046	10,154,354
Wilmer Cutler Pickering Hale and Door LLP	48,485	726,909
<b>Total Special Counsel Professionals</b>	<b>4,560,945</b>	<b>25,301,464</b>
<b>The Law Offices of Kenneth Feinberg (Mediator)</b>	<b>500,000</b>	<b>3,502,648</b>
<b>Phillips ADR (Mediator)</b>	<b>500,000</b>	<b>3,504,089</b>
<b>Bielli &amp; Klauder, LLC (Fee Examiner)</b>	<b>16,675</b>	<b>127,375</b>
<b>Tom Vilsack (Court appointed monitor)</b>	<b>14,175</b>	<b>148,475</b>
<b>Ernst &amp; Young (Canada), Court Appointed Information Officer</b>	<b>-</b>	<b>198,546</b>
<b>Total Retained Restructuring Professional Fees</b>	<b>\$ 22,640,419</b>	<b>\$ 211,243,005</b>

Footnotes

1) Represents payments made since the Commencement Date

2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period September 1, 2020 to September 30, 2020

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?	X		As disclosed in the Monthly Operating Report dated September 18, 2020, in the ordinary course, an insurer provided statutory notices of cancellation. The insurer that provided these notices has provided renewal quotes to the Debtor to renew the Debtors insurance programs on 10/1/2020 and these programs were renewed effective 10/1/2020. Debtors do not anticipate any interruption via cancellation of any necessary insurance coverages.
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?		X	
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	